Almirall reinforces its European expansion with the opening of new affiliates in Poland and Switzerland

·With an anticipated sales income of over 5 million euros, the Polish affiliate represents another step in Almirall’s pan-European expansion.

·The company is also opening up an affiliate in Switzerland.

·These affiliates’ product portfolio will initially consist of dermatological proprietary medicinal products.

Barcelona, 29 April 2008.- Almirall, the international pharmaceutical company based in Spain, is furthering its international expansion with the creation of a new affiliate in Poland to serve as a platform for taking on a large part of the Eastern European market. Besides being the 6^th largest pharma market in Europe with positive growth potential, establishing an affiliate in Poland represents another step in Almirall’s pan-European expansion.

Located in Warsaw, Almirall sp. z o.o. will start business with a staff of 23 people, which is expected to rise by 30% over the next three months. Sales income for the affiliate in 2008 is estimated to reach over 5 million euros.

In addition to this new office in Poland, Almirall has also consolidated a business unit in Switzerland, allowing it to further strengthen its position in the European market along with its existing affiliates in Germany, Austria, Belgium, France, Italy, Portugal and the United Kingdom-Ireland.

Luciano Conde, Chief Operating Officer, comments: “Almirall is working to consolidate its international expansion and presence in certain markets, with a particular focus on Europe. The start-up of these affiliates in Poland and Switzerland is a clear example of our progress. Besides, it will also help us to provide more European patients with our medicinal products”.

Medicinal portfolio

Over the next five years, the Polish affiliate’s core product portfolio will contain dermatological proprietary Almirall medicines, including those from the company’s latest acquisitions, such as Solaraze (keratosis actinica), Vaniqa (facial hirsutism) and Balneum (eczema and skin infections).

In the future the company is also intending to market aclidinium bromide, a proprietary R&D long-lasting antimuscarinic drug for sufferers from COPD (Chronic Obstructive Pulmonary Disease that is currently in Phase III clinical trials, and the results of which will be available in the second half of 2008.

Almirall

Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis and multiple sclerosis.

Almirall is currently present in over 70 countries with direct presence in Europe and Latin America.

For more information:

Ketchum/SEIS

Sonia San Segundo / Victoria Hernández

sonia.sansegundo@ketchum.com

Tel.: 91 788 32 00